Lil­ly backs Or­so­Bio's $60M Se­ries A for PhII tri­als in obe­si­ty and NASH

Or­so­Bio, a biotech fo­cused on obe­si­ty and meta­bol­ic dis­or­ders, is get­ting fi­nan­cial sup­port from one of the lead­ing drug­mak­ers in the field as Eli Lil­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER